Overall, the cabozantinib and Honokiol combination effectively targets the c-Met-induced and Nrf2-mediated antioxidant pathway in renal cancer, enhancing oxidative stress and promoting tumor cell death [141]. This evidence concerns the gene NFE2L2 and renal carcinoma.